# NeuroBo Pharmaceuticals Inc. (NRBO)

Source: https://www.quantisnow.com/company/NRBO
Generated: 2026-11-19T06:38:14.635Z

- Ticker: NRBO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2016
- Website: neurobopharma.com

## About

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

## Latest NRBO news and filings

- 2024-12-02 22:31 UTC [SEC Form 4] [CEO & President Kim Hyung Heon covered exercise/tax liability with 2,867 shares, decreasing direct ownership by 4% to 63,799 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-president-kim-hyung-heon-covered-exercisetax-liability-with-2867-5796503)
- 2024-11-29 14:10 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5794378)
- 2024-11-18 13:35 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-amendments-to-articles-5780105)
- 2024-11-18 13:01 UTC [NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-announces-strategic-realignment-ahead-of-important-clinical-milestones-5780003)
- 2024-11-14 20:34 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-neurobo-pharmaceuticals-inc-5775142)
- 2024-11-13 13:01 UTC [Conference Announcement] [NeuroBo Pharmaceuticals to Participate in Investor Conferences in November](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-november-5770079)
- 2024-11-07 21:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neurobo-pharmaceuticals-inc-5759178)
- 2024-11-07 13:01 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-5757812)
- 2024-11-07 13:01 UTC [NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-5757796)
- 2024-11-04 13:30 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5749543)
- 2024-10-07 11:00 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5717760)
- 2024-10-01 12:01 UTC [Conference Announcement] [NeuroBo Pharmaceuticals to Participate in Investor Conferences in October](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-october-5709523)
- 2024-09-30 12:07 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5707920)
- 2024-09-30 12:01 UTC [NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-announces-positive-top-line-data-from-the-sad-part-5707899)
- 2024-09-20 20:20 UTC [SEC Form 4] [Large owner Dong-A St Co., Ltd sold $1,526 worth of shares (407 units at $3.75), decreasing direct ownership by 0.01% to 5,347,792 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-dong-a-st-co-ltd-sold-1526-worth-of-5700909)
- 2024-09-20 20:15 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-neurobo-pharmaceuticals-inc-5700856)
- 2024-09-19 20:10 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-5699651)
- 2024-09-03 12:01 UTC [Conference Announcement] [NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference](https://www.quantisnow.com/insight/neurobo-to-participate-in-the-hc-wainwright-26th-annual-global-5679094)
- 2024-08-21 20:02 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-neurobo-pharmaceuticals-inc-5667715)
- 2024-08-14 21:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neurobo-pharmaceuticals-inc-5659961)
- 2024-08-14 12:01 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-5658301)
- 2024-08-14 12:01 UTC [Public Offering] [NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-5658294)
- 2024-08-13 20:01 UTC [SEC Form 4] [CEO & President Kim Hyung Heon covered exercise/tax liability with 11,467 shares, decreasing direct ownership by 15% to 66,666 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-president-kim-hyung-heon-covered-exercisetax-liability-with-11467-5656638)
- 2024-08-13 12:30 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5656218)
- 2024-08-13 12:01 UTC [NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-completes-enrollment-of-the-sad-part-1-of-5656116)
- 2024-08-07 12:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-neurobo-pharmaceuticals-inc-5646538)
- 2024-08-06 12:30 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5644034)
- 2024-08-06 12:01 UTC [NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-announces-joint-research-agreement-together-with-dong-a-st-5643948)
- 2024-07-30 12:30 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5632539)
- 2024-07-30 12:01 UTC [NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-announces-exclusive-license-agreement-with-mthera-pharma-for-5632472)
- 2024-07-25 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-neurobo-pharmaceuticals-inc-5626487)
- 2024-07-24 21:11 UTC [SEC Form 424B3] [SEC Form 424B3 filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-neurobo-pharmaceuticals-inc-5626132)
- 2024-07-18 12:21 UTC [SEC Form S-1] [SEC Form S-1 filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-neurobo-pharmaceuticals-inc-5614720)
- 2024-07-17 11:00 UTC [Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now](https://www.quantisnow.com/insight/presenting-on-the-emerging-growth-conference-73-day-2-on-5611791)
- 2024-07-16 12:30 UTC [SEC Form 8-K] [NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5609775)
- 2024-07-16 11:00 UTC [Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now](https://www.quantisnow.com/insight/presenting-on-the-emerging-growth-conference-73-day-1-on-5609377)
- 2024-07-11 12:01 UTC [Conference Announcement] [NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July](https://www.quantisnow.com/insight/neurobo-pharmaceuticals-to-present-at-the-emerging-growth-conference-in-5603333)
- 2024-07-10 15:11 UTC [Insider Buy] [Amendment: Large owner Dong-A St Co., Ltd bought $10,000,003 worth of shares (2,544,530 units at $3.93), increasing direct ownership by 91% to 5,348,229 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-large-owner-dong-a-st-co-ltd-bought-10000003-worth-5601558)
- 2024-07-01 20:05 UTC [SEC Form D] [SEC Form D filed by NeuroBo Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-neurobo-pharmaceuticals-inc-5586615)
- 2024-07-01 18:13 UTC [Market Chatter] [Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation](https://www.quantisnow.com/insight/watching-neurobo-pharmaceuticals-zacks-small-cap-research-gives-stock-22-price-5586334)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NRBO
- Earnings history: https://www.quantisnow.com/earnings/NRBO
- Dividend history: https://www.quantisnow.com/dividends/NRBO
- Insider transactions: https://www.quantisnow.com/insiders/NRBO
- Options chain: https://www.quantisnow.com/options/NRBO
- SEC 8-K filings only: https://www.quantisnow.com/company/NRBO/8-k
- RSS and alerts for NRBO: https://www.quantisnow.com/docs/rss-feeds.md
